Efficacy of an Intervention to Prevent Frailty in Obese Elderly People (PRE-FROB)
PRE-FROB
Efficacy of a Multimodal Intervention in the Prevention of Frailty in Obese Elderly People and Study of the Pathophysiological Mechanisms Involved
1 other identifier
interventional
319
1 country
1
Brief Summary
Rationale: There is increasing evidence that obesity may be a risk factor for frailty in the elderly. Obesity favors a state of chronic inflammation and insulin resistance, involves a fatty infiltration of the muscle and an increased cardiovascular risk and, in addition, obese people usually perform less physical activity. All this favors the loss of mass and muscular function (sarcopenia), a key component of the fragility and the functional deterioration. Objectives: To evaluate the effectiveness of a multimodal intervention to lose weight in the prevention of frailty in obese elderly people, as well as to know the main mechanisms involved in the frailty process. Methodology: Design: Controlled, randomized, open-label clinical trial with two parallel intervention arms and 2 years follow-up. Study population: People between 65 and 75 years of age, obese (BMI ≥30), without criteria of fragility and living in the community. Study intervention: multimodal and personalized intervention with the support of a "personal trainer" that has two main axes of action: a) diet: assessment of nutritional status and nutritional requirements and establishment of personalized nutritional plan with monthly dietetic controls and b) physical exercise: a multi-component physical exercise program that will include aerobic exercise and strengthening, balance and flexibility exercises as well as a weekly group session of health education, during six months. Main outcome measures (to be evaluated annually for 2 years): Fragility (according to the L Fried criteria) and Sarcopenia (according to the criteria of the European Working Group on Sarcopenia in Older People -EWGSOP). Sarcopenia is considered if there is a decrease in gait velocity or muscle grip strength (measured with a dynamometer) and a decrease in muscle mass assessed by bioimpedance (BIA). Intermediate outcome measures (at 6, 12 and 24 months): a) weight loss, b) changes in body composition and distribution of body fat, c) glycemic control (HbA1) and insulin resistance (by HOMA index (HOmeostasis Model Assessment)), d) cardiovascular risk according to the REGICOR algorithm, e) functional capacity (according to Barthel Index and 2 Minute Walking Test), f) inflammatory markers (IL-6, CRP(C reactive protein), TNF(Tumor Necrosis Factor)-alpha and leptin) and g) anabolic hormones (IGF-1, ghrelin and testosterone).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 20, 2016
CompletedFirst Posted
Study publicly available on registry
December 22, 2016
CompletedStudy Start
First participant enrolled
January 23, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 26, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 20, 2019
CompletedJuly 22, 2020
July 1, 2020
2.3 years
December 20, 2016
July 21, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Frailty
Frailty by L Fried criteria
two years
Secondary Outcomes (1)
Sarcopenia
two years
Study Arms (2)
Intervention
EXPERIMENTAL* diet: assessment of nutritional status and nutritional requirements and establishment of personalized nutritional plan with monthly dietetic controls. * physical exercise: a multi-component physical exercise program that will include aerobic exercise and strengthening, balance and flexibility exercises as well as a weekly group session of health education, during six months.
Control
NO INTERVENTIONClinical practise
Interventions
Eligibility Criteria
You may qualify if:
- BMI between 30 and 39 kg / m2
- Non Frail according to L. Fried criteria
- At least one of the following diagnoses:
- Oral glucose intolerance or type 2 diabetes without insulin therapy.
- Dyslipidemia (cholesterolemia\> 200 mg / dl or triglyceridemia\> 150 mg / dl)
- Arterial hypertension (AT\> 120/90 mm Hg)
- Relevant physical limitations due to obesity
- Sleep apnea-hypopnea syndrome (SAHS)
- Give written informed consent to participate in the study.
You may not qualify if:
- Dementia or other neurodegenerative diseases (Parkinson's disease)
- Neuromuscular diseases
- Severe psychiatric illness that, at the discretion of the physician, prevents good compliance with the study intervention
- Active cancer
- Life expectancy less than 6 months
- Hemiplegia secondary to stroke
- Amputation of a member
- Bariatric surgery tributary patient
- Institutionalized patient
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Consorci Sanitari del Maresme
Mataró, Barcelona, 08304, Spain
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 20, 2016
First Posted
December 22, 2016
Study Start
January 23, 2017
Primary Completion
April 26, 2019
Study Completion
December 20, 2019
Last Updated
July 22, 2020
Record last verified: 2020-07
Data Sharing
- IPD Sharing
- Will not share